Related Experiment Videos
Overview of pharmacological treatment of Kawasaki disease
1Division of Paediatrics, Children's Research Hospital, Kyoto, Prefectural University of Medicine, Japan.
Insights
Kawasaki disease treatment has advanced with intravenous gamma-globulin (IVGG), significantly reducing coronary aneurysms. Research now focuses on effective therapies for IVGG-resistant cases, improving outcomes for children with this condition.
Area of Science:
- Pediatrics
- Immunology
- Cardiology
Background:
- Kawasaki disease etiology remains unknown despite 32 years of research.
- Conventional therapies like corticosteroids and aspirin have limited efficacy in preventing coronary artery aneurysms.
- High-dose aspirin may show racial differences in salicylate sensitivity and fever duration.
Purpose of the Study:
- To review the advancements in Kawasaki disease treatment.
- To highlight the impact of intravenous gamma-globulin (IVGG) as a standard therapy.
- To discuss current research directions for IVGG-resistant cases.
Main Methods:
- Literature review of Kawasaki disease research and treatment modalities.
- Analysis of treatment outcomes, particularly coronary artery aneurysm incidence.
- Examination of therapeutic strategies for resistant cases.
Main Results:
- Intravenous gamma-globulin (IVGG) is now a standard therapy, reducing persistent coronary aneurysms to 1.9%.
- Corticosteroid-resistant patients have a higher incidence of coronary artery aneurysms.
- Pulsed methylprednisolone or repeated IVGG administration are recommended for IVGG-resistant Kawasaki disease.
Conclusions:
- IVGG has revolutionized Kawasaki disease treatment, significantly improving outcomes.
- Further research is crucial for optimizing treatment in IVGG-resistant patients.
- Understanding pathogenesis and clinical features continues to drive therapeutic advances.
Abstract:
Kawasaki disease has been researched for 32 years but its aetiology is still unknown. Conventional therapy for the disease includes corticosteroids and aspirin (acetylsalicylic acid) as anti-inflammatory and/or antithrombotic agents but they have not been proven to prevent coronary artery aneurysms. Although a high incidence of liver dysfunction in Japanese patients with Kawasaki disease receiving high dose aspirin (> or =80 mg/kg/day) suggests racial differences in salicylate sensitivity, the duration of fever in patients receiving high dose aspirin is shorter than that in patients receiving moderate dosages (30 to 50 mg/kg/day). Furthermore, most corticosteroid-resistant patients were found to develop coronary artery aneurysms, many of which were large. With the clarification of the pathogenesis and clinical features of Kawasaki disease, advances in its treatment have been achieved. The introduction of high-dose intravenous gamma-globulin (IVGG) was an epoch in this field and IVGG is now a standard therapy with the incidence of persistent coronary aneurysms 1.9% in children with the disease receiving IVGG. Today, research is mainly directed toward the treatment of IVGG-resistant patients. One to 3 days of pulsed doses of methylprednisolone (30 mg/kg/day) or readministration of IVGG 1 g/kg (once to several times) has been recommended for patients with IVGG-resistant Kawasaki disease.